ABION Inc. is a Korea-based company principally engaged in the research, development and sales of pharmaceuticals. Along with its subsidiaries, the Company operates its business through four segments including product segment, contract research organization (CRO) service segment, research segment and other segment. The Product segment produces and sells diagnostic reagents, research reagents, and stem cell culture medium. The CRO Service segment provides histopathology analysis, molecular genetic analysis, cellular immunoassay, and antibody detection services. The Research segment is engaged in research and development of drugs for protein therapeutics, nucleic acid therapeutics, and antibody therapeutics.

Employees

Sector

Biotechnology & Medical Research

Calendar

10-08 - Significant Split/Dividend

More about the company

Quotes

Date	Price	Change	Volume
26-07-14	₩627.00	-5.00%	994,348
26-07-13	₩660.00	-11.53%	648,193
26-07-10	₩746.00	+11.34%	539,535
26-07-09	₩670.00	-1.90%	488,265
26-07-08	₩683.00	-11.87%	711,079

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. Other stock markets 2026-07-14			5-day change	1st Jan Change
627.00 ^KRW	-5.00%		-21.13%	-79.97%

04-07	ABION Announces Preclinical Data Showing IFN-? Antibody Fusion Abn202 Outperforms Trop2-Targeting ADCs	CI
25-04-04	Abion To Divest 5.9 Billion Won Worth Of Shares In Vivozon Inc	RE

Market Cap	56.49B 37.96M 33.27M 30.73M 28.36M 53.39M 3.65B 54.46M 367M 144M 1.78B 143M 139M 6.17B	P/E 2024	-4.02x	P/E 2025	-7.21x
Enterprise Value	28.16B 18.92M 16.59M 15.32M 14.14M 26.61M 1.82B 27.15M 183M 71.64M 889M 71.07M 69.5M 3.08B	EV / Sales 2024	282x	EV / Sales 2025	288x
Free-Float	67.22%	Yield 2024 *	-	Yield 2025	-

04-07	ABION Announces Preclinical Data Showing IFN-? Antibody Fusion Abn202 Outperforms Trop2-Targeting ADCs	CI
25-04-04	Abion To Divest 5.9 Billion Won Worth Of Shares In Vivozon Inc	RE
24-12-29	Nuon Co., Ltd. completed the acquisition of 4.06% stake in ABION Inc. from KPM TECH Co., Ltd..	CI
24-12-25	KPM TECH Co., Ltd. announced that it has received KRW 5.999999711 billion in funding from ABION Inc.	CI
24-12-22	Nuon Co., Ltd. agreed to acquire 4.06% stake in ABION Inc. from KPM TECH Co., Ltd. for KRW 8 billion.	CI
24-12-22	ABION Inc. announced that it has received KRW 8.0011152 billion in funding from TELCON RF PHARMACEUTICAL. Inc.	CI
24-12-17	KPM TECH Co., Ltd. announced that it expects to receive KRW 5.999999711 billion in funding from ABION Inc.	CI
24-12-04	ABION Inc. completed the acquisition of 7.56% stake in Vivozon, Inc. from TELCON RF PHARMACEUTICAL. Inc..	CI
24-12-04	ABION Inc. announced that it has received KRW 20.019993378 billion in funding from TELCON RF PHARMACEUTICAL. Inc.	CI
24-11-10	ABION Inc. announced that it expects to receive KRW 20.019993378 billion in funding from TELCON RF PHARMACEUTICAL. Inc.	CI
24-11-10	ABION Inc. agreed to acquire 7.56% stake in Vivozon, Inc. from TELCON RF PHARMACEUTICAL. Inc. for KRW 20.1 billion.	CI
24-10-27	ABION Inc. announced that it expects to receive KRW 9.999995616 billion in funding from TELCON RF PHARMACEUTICAL. Inc.	CI
23-12-27	Abion Inc. announced that it has received KRW 7.999997049 billion in funding from TELCON RF PHARMACEUTICAL. Inc., Gencurix Inc.	CI

1 day	-5.00%
1 week	-21.13%
Current month	-26.41%
1 month	-48.82%
3 months	-74.82%
6 months	-81.98%
Current year	-79.97%

Abion Inc. Stock

Stocks

A203400

KR7203400007

Biotechnology & Medical Research

Valuation: Abion Inc.

Chart: Abion Inc.

Latest news : Abion Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Abion Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	574	785
1 month	570	1,351
Current year	570	4,335
1 year	570	5,750
3 years	570	7,277.78
5 years	570	14,694.44
10 years	570	14,694.44

Manager	Title	Age	Since
Young-Gi Shin CEO	Chief Executive Officer	55	2010-07-31
Seong-Yun Woo DFI	Director of Finance/CFO	45	2025-03-27
Gi-Ryong Jang COO	Chief Operating Officer	46	2025-12-31

Director	Title	Age	Since
Young-Gi Shin BRD	Director/Board Member	55	2014-12-30
Jin-Wook Yang BRD	Director/Board Member	56	2022-03-24
Geun-Chul Park BRD	Director/Board Member	70	-

Date	Insider	Type	Quantity	% Market Cap.
12-07	Sun-mi Chang	Free	27	0.0001%
12-07	Sun-mi Chang	Buy	34	0.0001%
12-07	Yang-mi Lim	Free	92	0.0002%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ABION INC.	-5.00%	-21.13%	-86.86%	-84.43%	39.82M
WUXI APPTEC CO., LTD.	+6.05%	+3.69%	+65.28%	+89.94%	53.54B
ARGENX SE	+0.21%	-6.28%	+56.18%	+127.90%	54.18B
INSMED INCORPORATED	+0.89%	-2.42%	+8.07%	+434.51%	23.66B
BIONTECH SE	+0.37%	-4.13%	-18.56%	-16.48%	22.78B
WUXI BIOLOGICS (CAYMAN) INC.	+2.36%	+3.86%	+42.80%	-6.60%	19.54B
GENMAB A/S	-2.29%	-1.92%	+35.57%	-29.14%	17.82B
PHARMAESSENTIA CORPORATION	-4.00%	-7.88%	+175.60%	+343.60%	16.01B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.15%	-3.07%	+45.33%	+654.85%	15.37B
EXELIXIS, INC.	-0.48%	-2.30%	+22.36%	+187.62%	14.09B
Average	-0.30%	-2.14%	+34.58%	+170.18%	23.7B
Weighted average by Cap.	+1.19%	-0.46%	+48.93%	+165.42%

	2024	2025
Net sales	760M 511K 447K 413K 381K 718K 49.1M 732K 4.93M 1.93M 24M 1.92M 1.87M 83M	880M 591K 518K 479K 442K 832K 56.89M 848K 5.72M 2.24M 27.8M 2.22M 2.17M 96.16M
Net income	-43.38B -29.15M -25.55M -23.6M -21.78M -41M -2.8B -41.82M -282M -110M -1.37B -109M -107M -4.74B	-29.06B -19.53M -17.12M -15.81M -14.59M -27.46M -1.88B -28.02M -189M -73.94M -918M -73.36M -71.73M -3.18B
Net Debt	14.05B 9.44M 8.27M 7.64M 7.05M 13.27M 908M 13.54M 91.23M 35.73M 444M 35.45M 34.67M 1.53B	-28.33B -19.04M -16.69M -15.41M -14.22M -26.78M -1.83B -27.31M -184M -72.08M -895M -71.51M -69.93M -3.1B